Binimetinib binimetinib

Drug Class

MEK inhibitor

Mechanism

Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2, blocking the MAPK pathway in BRAF-mutant cancer cells.

Approved Indication

Treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with encorafenib.

What This Means For Patients

Binimetinib is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2018) — Sources
• EMA — Approved (2018) — Sources

Pivotal Clinical Evidence

• COLUMBUS — Dummer et al., Lancet Oncol 2018 (NCT01909453) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi
• https://doi.org/10.1016/S1470-2045(18)30142-6